ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4697-4704

  Qin, Xiuguang ^a   Yao, Wenjian ^a   Li, Weiwei ^a   Feng, Xianjun ^a   Huo, Xiaoqing ^a   Yang, Shujuan ^b   Zhao, Hui ^c   Gu, Xiaomeng ^c  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

BRCA1; Clinical outcome; ERCC1; mRNA; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; NUCLEIC ACID BINDING PROTEIN; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP G PROTEIN; BRCA1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DNA SYNTHESIS; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RNA ISOLATION; THORAX RADIOGRAPHY; TREATMENT DURATION; XERODERMA; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84902951267     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1615-8     Document Type: Article

References (27)

1. International Agency for Research on Cancer. Globocan 2008: Lung cancer incidence, mortality and prevalence worldwide in 2008. Summary. http://globocan.iarc.fr/factsheet.asp.
2. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer. 2009;10(1):47-52.
3. Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res. 2012;32(11):5003-10.
4. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2011;28(4):1411-7.
5. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic nonsmall-cell lung cancer. An Italian Trials in Medical Oncology Study. Ann Oncol. 2007;18:461-7. (Pubitemid 46359623)
6. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64:131-9.
7. Johnson DH. Gemcitabine for the treatment of non-small-cell lung cancer. Oncology (Williston Park). 2001;15(3 Suppl 6):33-9. (Pubitemid 33739202)
8. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000;57(8-9):1229-35. (Pubitemid 30663480)
9. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2000;89(2):160-6. (Pubitemid 30185925)
10. Cai Y, Geacintov NE, Broyde S. Nucleotide excision repair efficiencies of bulky carcinogen-DNA adducts are governed by a balance between stabilizing and destabilizing interactions. Biochemistry. 2012;51(7):1486-99.
11. Sugasawa K. Xeroderma pigmentosum genes: functions inside and outside DNA repair. Carcinogenesis. 2008;29:455-65. (Pubitemid 351418943)
12. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13:2443-9. (Pubitemid 39377848)
13. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res. 2013;5:327-36.
14. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012;7(6):973-81.
15. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. Bio-FAST trial group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108(8):1695-703.
16. Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res. 2012;31:25.
17. Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer. 2012;75(3):306-12.
18. Wei J, Zou ZY, Qian XP, Wang LF, Yu LX, Liu BR. ERCC1 mRNA expression levels and outcome of gastric cancer patients receiving oxaliplatin-based chemotherapy. Zhonghua Bing Li Xue Za Zhi. 2008;37(8):551-2.
19. Bai ZL, Wang YY, Zhe H, He JL, Hai P. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol. 2012;7:221.
20. Baba H, Watanabe M, Okabe H, Miyamoto Y, Sakamoto Y, Baba Y, et al. Upregulation of ERCC1 and DPD expressions after oxaliplatinbased first-line chemotherapy for metastatic colorectal cancer. Br J Cancer. 2012;107(12):1950-5.
21. Liu GY, Qu QX, Mi RR, Qi J. Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer. Zhonghua Zhong Liu Za Zhi. 2008;30(3):184-7.
22. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(19):2404-12.
23. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(4):663-71.
24. Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010;70:63-70.
25. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al. BRCA1 functions as a differential modulator of chemotherapyinduced apoptosis. Cancer Res. 2003;63:6221-8. (Pubitemid 37255167)
26. Han Y, Wang XB, Xiao N, Liu ZD. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(5):2987-90.
27. Wang L, Meng L, Wang XW, Ma GY, Chen JH. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2013.